alexa A Phase 1 Clinical Trial Of Hantaan Virus And Puumala Virus M-segment DNA Vaccines For Hemorrhagic Fever With Renal Syndrome Delivered By Intramuscular Electroporation
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Connie S Schmaljohn
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
H emorrhagic fever with renal syndrome (HFRS) is caused by infection with the Hanta viruses Hantaan (HTNV), Seoul (SEOV), Puumala (PUUV), or Dobrava (DOBV) viruses. We developed candidate DNA vaccines for HFRS expressing the envelope glycoprotein genes of HTNV or PUUV and evaluated them in an open-label, single-center phase 1 study. Three groups of nine subjects each were vaccinated on days 0, 28 and 56 with the DNA vaccines for HTNV, PUUV, or mixture of both vaccines using the Ichor Medical Systems intramuscular electroporation delivery device. Each vaccination consisted of 2.0 mg DNA in an injected volume of 1 mL saline. There were no study-related serious adverse events. Neutralizing antibody responses were detected in 5/9 and 7/9 individuals who completed all three vaccinations with the HTNV or PUUV DNA vaccines, respectively. In the combined vaccine group, 7/9 of the volunteers receiving all three vaccinations developed neutralizing antibodies to PUUV. The three strongest responders to the PUUV vaccine also had strong neutralizing antibody responses to HTNV. These results demonstrate that the HTNV and PUUV DNA vaccines delivered by electroporation separately or as a mixture are safe. In addition, both vaccines were immunogenic, although when mixed together, more subjects responded to the PUUV than to the HTNV DNA vaccine, suggesting immunological interference. Consequently, we have developed an optimized HTNV DNA vaccine that shows no interference in hamsters when mixed with the PUUV vaccine. Additional clinical testing of this new bivalent formulation is currently in progress
Connie S Schmaljohn is the U.S. Army Senior Research Scientist for Medical Defenses against Infectious Diseases. Her studies focus on the development of molecular vaccines for biodefense, and on the molecular biology of highly pathogenic viruses
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version